当前位置: 首页 > 期刊 > 《中国医学创新》 > 2021年第18期
编号:185886
紫杉醇联合洛铂化疗方案对子宫颈癌患者血清HGF、VEGF、TSGF水平的影响
http://www.100md.com 2021年3月27日 中国医学创新 2021年第18期
血管内皮生长因子
     陈少辰

    7月-2020年3月本院收治的103例子宫颈癌患者作为研究对象,根据随机数表法将其分为A组51例(紫杉醇联合顺铂治疗)与B组52例(紫杉醇联合洛铂化疗方案治疗)。两组均行子宫全切术。疗程结束后,对比两组临床疗效、HGF、VEGF、TSGF及毒副反应。结果:两组治疗总有效率对比,差异无统计学意义(P>0.05);治疗4个周期后,两组HGF、VEGF、TSGF水平较治疗前均降低,且B组均低于A组,差异均有统计学意义(P<0.05);B组消化道反应、白细胞下降人数均较A组少,差异均有统计学意义(P<0.05)。结论:子宫颈癌患者采取紫杉醇联合洛铂化疗治疗,能够有效降低HGF、VEGF、TSGF水平,抑制肿瘤生长,且毒副反应较轻,治疗具有一定安全性。

    【关键词】 子宫颈癌 紫杉醇 洛铂 肿瘤特异性生长因子 血管内皮生长因子 肝细胞生长因子

    [Abstract] Objective: To investigate the effect of Paclitaxel combined with Lobaplatin chemotherapy on serum hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF) and malignant tumor specific growth factor (TSGF) in patients with cervical cancer. Method: A total of 103 patients with cervical cancer admitted to our hospital from July 2018 to March 2020 were selected as the research objects. According to the random number table method, they were divided into 51 cases in group A (Paclitaxel combined with Cisplatin treatment) and 52 cases in group B (Paclitaxel combined with Lobaplatin chemotherapy regimen). Both groups underwent total hysterectomy. After the course of treatment ......

您现在查看是摘要页,全文长 12123 字符